This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Propper, D. J. Articles by Ganesan, T. S. Search for Related Content PubMed PubMed Citation Articles by Propper, D. J. Articles by Ganesan, T. S.

Low-Dose IFN- Induces Tumor MHC Expression in Metastatic Malignant Melanoma

Imperial Cancer Research Fund Medical Oncology Unit, University of Oxford, Churchill Hospital, Oxford X3 7LJ [D. J. P., J. P. B., H. T., N. D., K. G., D. C. T., A. L. H., T. S. G.]; Nuffield Department of Surgery, University of Oxford, Oxford OX3 9DU [D. C., P. B.]; and Imperial Cancer Research Fund Laboratories, London WC2A 3PX [P. T., F. B.], United Kingdom

Specific antitumor immune responses require expression of MHC class I or II molecules on tumor cells, and MHC antigen down-regulation is a presumed tumor growth promoting mechanism. Because IFN- up-regulates tumor MHC antigen expression in vitro, in this Phase II trial of an immunologically active dose and schedule we evaluated whether this was the case in vivo. Twenty-three patients with metastatic melanoma were treated with IFN- 100 µg/m² s.c. once weekly for a maximum of 6 months. There were three complete responses, now maintained for 53, 36, and 25 months. The remainder had progressive disease. The treatment was well tolerated, with no toxicity exceeding National Cancer Institute Common Toxicity Criteria grade II. Immunohistochemical analysis of tumor biopsies during treatment was performed using monoclonal antibodies to HLA class I (W/632) and class II (CR3/43) monomorphic determinants. HLA class I was down-regulated in 2 of 19 patients pretreatment and up-regulated by IFN- in both. HLA class II was down-regulated pretreatment in 14 of 18 patients and up-regulated by IFN- in 6 (43%). The HLA up-regulation persisted throughout the study. IFN- induced significant but short-lived up-regulation of surrogate markers of monocyte activation (serum neopterin) and class I up-regulation (serum ß-2-microglobulin) in most patients. There was no consistent relationship between surrogate marker up-regulation, tumor antigen up-regulation, and responses. The study shows that the significant immune modulation induced by IFN- does not correlate with tumor responses and that the serum surrogate marker changes do not reflect tumor events. The durable and long-lived responses, clear demonstration of tumor MHC up-regulation, and low toxicity suggest that weekly IFN- 100 µg/m² would be a useful addition to chemoimmunotherapeutic regimens.

This article has been cited by other articles:

				E. C. de Bruin, C. J.H. van de Velde, J. H. J.M. van Krieken, C. A.M. Marijnen, and J. P. Medema Epithelial Human Leukocyte Antigen-DR Expression Predicts Reduced Recurrence Rates and Prolonged Survival in Rectal Cancer Patients Clin. Cancer Res., February 15, 2008; 14(4): 1073 - 1079. [Abstract] [Full Text] [PDF]

				L. Vujanovic, M. Mandic, W. C. Olson, J. M. Kirkwood, and W. J. Storkus A Mycoplasma Peptide Elicits Heteroclitic CD4+ T Cell Responses against Tumor Antigen MAGE-A6 Clin. Cancer Res., November 15, 2007; 13(22): 6796 - 6806. [Abstract] [Full Text] [PDF]

				R. L. Ferris, T. L. Whiteside, and S. Ferrone Immune Escape Associated with Functional Defects in Antigen-Processing Machinery in Head and Neck Cancer. Clin. Cancer Res., July 1, 2006; 12(13): 3890 - 3895. [Abstract] [Full Text] [PDF]

				T. E. Battle, R. A. Lynch, and D. A. Frank Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis. Cancer Res., April 1, 2006; 66(7): 3649 - 3657. [Abstract] [Full Text] [PDF]

				P. S. Mobberley-Schuman and A. A. Weiss Influence of CR3 (CD11b/CD18) Expression on Phagocytosis of Bordetella pertussis by Human Neutrophils Infect. Immun., November 1, 2005; 73(11): 7317 - 7323. [Abstract] [Full Text] [PDF]

				F. Curnis, A. Gasparri, A. Sacchi, A. Cattaneo, F. Magni, and A. Corti Targeted Delivery of IFN{gamma} to Tumor Vessels Uncouples Antitumor from Counterregulatory Mechanisms Cancer Res., April 1, 2005; 65(7): 2906 - 2913. [Abstract] [Full Text] [PDF]